Genmab — September 2017
-
Merck buys Rigontec ; another immuno-oncology combo?
http://www.epvantage.com/Universal/View.aspx?type=Story&id=729882&isEPVantage=yes -
meanwhile, the company that had to put Opdivo on partial clinical hold , has some succes with.... Opdivo
https://investors.bms.com/iframes/press-releases/press-release-details/2017/CheckMate--214-Study-Evaluating-Opdivo-in-Combination-with-Yervoy-Stopped-Early-for-Demonstrating-Overall-Survival-Benefit-in-Patients-with-Previously-Untreated-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspx -
-
God morgen.
-
Her er en opsummering af sammenhæng mellem Exel og Opdivo/Yervoy succes i RCC https://seekingalpha.com/news/3294186-exelixis-9-percent-bristol-myers-successful-study-opdivo-yervoy-rcc?app=1&uprof=45&dr=1#email_link
-
CPH, hvilken betydning har det i forhold til det tekniske?
-
https://www.investing.com/equities/genmab-technical er altid god som hurtigt overblik hvis man er til det tekniske
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind